1.
Summary of key CD19 CAR T-cell clinical trials for the treatment of lymphoma
| Study | Phase | Lymphoma subtype | Patients (n) | CAR-T product | Efficacy (%) | Safety (%) |
| Schuster et al.34 | 1/2 | R/R | 28 | CTL019 | ORR | 3/4 CNS: 11 |
| DLBCL & FL | 2nd generation; 41BB | DLBCL: 43 | 3/4 CRS: 18 | |||
| Lentiviral vector | FL: 71 | |||||
| Schuster et al.35 | 2 | R/R DLBCL | 81 | CTL019 | ORR: 53.1 | 3/4 CNS: 12 |
| 2nd generation; 41BB | CRR: 39.5 | 3/4 CRS: 23 | ||||
| Lentiviral vector | ||||||
| ZUMA-140 | 1/2 | R/R DLBCL | 101 | Axi-cel | ORR: 82 | 3/4 CNS: 28 |
| PMBCL | 2nd generation; CD28 | CRR: 58 | 3/4 CRS: 14 | |||
| TFL | Retroviral vector | |||||
| Turtle et al.47 | 1 | R/R B-cell NHL | 32 | JCAR014 | ORR | 3/4 CNS: 28 |
| 2nd generation; 41BB | Cy/Etop conditioning: 50 | 3/4 CRS: 12.5 | ||||
| 1:1 ratio of CD4+and
CD8+T-cells |
||||||
| Retroviral vector | Cy/Flu conditioning: 72 | |||||
| Abramson et al.49 | 1 | R/R DLBCL | 74 | JCAR017 | DL1 (5*107CAR-T cells) | 3/4 CNS: 14 |
| PMBCL | 2nd generation; 41BB | ORR: 40 | 3/4 CRS: 1 | |||
| MCL | Defined ratio of CD4+and
CD8+T-cells |
CRR: 27 | ||||
| FL | Retroviral vector | DL2 (1*108CAR-T cells) | ||||
| ORR: 63 | ||||||
| CRR: 58 |